Get the Stockscreener App
84.18
0.70%
0.62
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Medtronic Plc stock is traded at $84.18, with a volume of 510.60K.
It is up +0.70% in the last 24 hours and down -5.31% over the past month.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
See More
Previous Close:
$83.56
Open:
$84.48
24h Volume:
510.60K
Relative Volume:
0.07
Market Cap:
$107.15B
Revenue:
$33.20B
Net Income/Loss:
$4.26B
P/E Ratio:
25.59
EPS:
3.29
Net Cash Flow:
$5.47B
1W Performance:
-0.02%
1M Performance:
-5.31%
6M Performance:
-6.58%
1Y Performance:
+3.99%
1-Day Range:
$83.88
$84.74
1-Week Range:
$82.95
$85.08
52-Week Range:
$75.96
$96.25
Medtronic Plc Stock (MDT) Company Profile
Name
Medtronic Plc
Sector
Industry
Phone
01135314381700
Address
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
Compare MDT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDT
Medtronic Plc
|
84.12 | 107.15B | 33.20B | 4.26B | 5.47B | 3.29 |
|
ABT
Abbott Laboratories
|
132.40 | 223.47B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.47 | 150.72B | 17.55B | 2.03B | 2.37B | 1.37 |
|
SYK
Stryker Corp
|
365.15 | 139.34B | 22.60B | 2.99B | 3.49B | 7.76 |
|
EW
Edwards Lifesciences Corp
|
76.21 | 44.54B | 5.54B | 4.18B | 259.90M | 7.00 |
Medtronic Plc Stock (MDT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Upgrade | Citigroup | Neutral → Buy |
| Oct-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-24 | Reiterated | Oppenheimer | Perform |
| Aug-15-24 | Upgrade | UBS | Sell → Neutral |
| Aug-14-24 | Downgrade | Stifel | Buy → Hold |
| May-30-24 | Initiated | Goldman | Sell |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-24-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-29-23 | Downgrade | UBS | Buy → Sell |
| Jan-09-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-23-22 | Downgrade | Citigroup | Buy → Neutral |
| Nov-23-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Aug-24-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Jun-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-10-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Dec-15-20 | Upgrade | Goldman | Sell → Neutral |
| Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-08-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Oct-08-20 | Upgrade | Stifel | Hold → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| May-14-20 | Downgrade | DZ Bank | Buy → Hold |
| Mar-30-20 | Downgrade | Needham | Strong Buy → Buy |
| Mar-25-20 | Upgrade | DZ Bank | Hold → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Sell |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-02-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-05-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Feb-04-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Jan-02-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Aug-27-18 | Reiterated | Argus | Buy |
View All
Medtronic Plc Stock (MDT) Latest News
Medtronic (MDT) Rises Higher Than Market: Key Facts - Nasdaq
Medtronic wins FDA approval for defibrillation lead - MedTech Dive
Medtronic Education Program Opens Doors for Employees - Yahoo Finance
Medtronic study backs automated neuromod for overactive bladder - MassDevice
Medtronic and Abbott's game-changing partnership for CGM integration - Today's Medical Developments
4 PFA studies in the spotlight at Heart Rhythm 2025 - MedTech Dive
Medtronic Gets FDA Nod for Smallest-Diameter, Lumenless Defibrillation Lead - Diagnostic and Interventional Cardiology
Earnings Preview: What To Expect From Medtronic’s Report - Nasdaq
Medtronic has positive VenaSeal data - MassDevice
Functional Endoscopic Sinus Surgery Market Key Players - openPR.com
Medtronic submits Hugo soft tissue robot for FDA approval - MedTech Dive
Medtronic inks new distro agreement for Retia Medical Argos cardiac output monitor - MassDevice
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic - Zacks Investment Research
Medtronic’s defibrillation lead gains FDA approval for use in right ventricle - Yahoo Finance
Medtronic Files for FDA Submission for the Hugo Robotic System - Medical Device and Diagnostic industry
Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients - BioSpace
Smoke Evacuation System Market to Garner $196.4 Million by 2027 | - openPR.com
Medtronic receives US FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure lead - Pharmabiz.com
Medtronic (MDT) Showcases Positive AFib Treatment Results at Key Medical Conference | MDT Stock News - GuruFocus
Medtronic (MDT) Reveals Promising AFib Treatment Outcomes with S - GuruFocus
Medtronic reports more positive outcomes with Affera PFA tech - MassDevice
Medtronic Affera pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients - Investing News Network
Medtronic PLC Says Sphere-360 Study Shows 88% Freedom From Arrhythmia Recurrence - marketscreener.com
Breakthrough: Medtronic's New AFib Treatment Achieves 88% Freedom from Arrhythmia with Zero Safety Issues - Stock Titan
Medtronic submits Hugo surgical robot to FDA, meets trial endpoints - MassDevice
Medtronic (MDT) Seeks FDA Approval for Hugo Robotic Surgery Syst - GuruFocus
Medtronic seeks FDA nod for Hugo robotic surgery system (MDT) - Seeking Alpha
2 Outstanding Dividend Stocks to Buy and Hold For 20 Years - The Motley Fool
Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery systemApr 26, 2025 - Medtronic
Medtronic (NYSE:MDT) Secures FDA Approval For Innovative OmniaSecure Defibrillation Lead - Yahoo Finance
Medtronic wins FDA nod for world’s smallest defibrillation lead - MassDevice
Medtronic (MDT) Gains FDA Approval for Advanced Defibrillation L - GuruFocus
Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical study results - Medtronic
Medtronic's Revolutionary 4.7F Defibrillation Lead Gets FDA Green Light with 100% Trial Success - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Medtronic signs distro deal to bring Dragonfly Endoscopy tech to U.S. - MassDevice
Medtronic (MDT) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Medtronic seeks FDA nod for insulin pump, furthering Abbott collab - MedTech Dive
Medtronic submits interoperable insulin pump to FDA to advance collaboration with Abbott - MassDevice
Medtronic announces distribution agreement with Dragonfly™* Endoscopy, expanding innovation in pancreaticobiliary endoscopy - Medtronic
Medtronic seeks FDA nod for insulin pump (MDT:NYSE) - Seeking Alpha
Medtronic : announces distribution agreement with Dragonfly™* Endoscopy, expanding innovation in pancreaticobiliary endoscopy - marketscreener.com
Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump - BioSpace
Medtronic seeks FDA clearance for interoperable insulin pum By Investing.com - Investing.com India
Medtronic seeks FDA clearance for interoperable insulin pum - Investing.com
Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump | MDT Stock News - GuruFocus
Medtronic : expands its Acute Care & Monitoring portfolio with a new distribution agreement for the Argos™ cardiac output monitor - marketscreener.com
Insulin Patch Pump Market Key Players AnalysisMedtronic Plc, Roche Diagnostic, Valerius, CeQur, Debiotech S.A. - openPR.com
Medtronic (MDT) Rises But Trails Market: What Investors Should Know - Yahoo Finance
Medtronic: Time To Buy This Dividend Aristocrat Bargain (NYSE:MDT) - Seeking Alpha
Orchestra BioMed Says AVIM Therapy Gets US FDA Breakthrough Device Designation - marketscreener.com
Medtronic Plc Stock (MDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.29%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):